Hauschild A, et al. - In a previous trial, dabrafenib plus trametinib vs placebo has been reported to improve relapse-free survival (RFS) (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF V600–mutant stage III melanoma, researchers estimated the fraction of patients expected to remain relapse free long term via an updated RFS analysis on the basis of extended study follow-up and a cure-rate model analysis. For 12 months, adjuvant dabrafenib plus trametinib vs placebo was randomly administered to patients with resected BRAF V600–mutant stage III melanoma in this phase III trial. According to findings, dabrafenib plus trametinib offered RFS benefit as confirmed in longer follow-up. Benefits of dabrafenib plus trametinib were seen in patients regardless of baseline factors, as noted in subgroup analysis.